March 23, 2018 / 2:58 PM / 3 months ago

BRIEF-CSL Behring Announces First Patient Enrollment In Phase 3 Clinical Trial Of CSL112

March 23 (Reuters) - Csl Ltd:

* CSL BEHRING ANNOUNCES FIRST PATIENT ENROLLMENT IN PHASE 3 CLINICAL TRIAL OF CSL112 TO ASSESS REDUCTION OF EARLY RECURRENT CARDIOVASCULAR EVENTS IN HEART ATTACK SURVIVORS

* CSL BEHRING -TRIAL TO EVALUATE EFFICACY, SAFETY OF CSL112 FOR REDUCTION OF EARLY RECURRENT CARDIOVASCULAR EVENTS FOLLOWING ACUTE MYOCARDIAL INFARCTION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below